Earlier, Relmada Therapeutics Announced Publication Of Results From The Phase 3 Reliance I Study of REL-1017 In The Journal Of Clinical Psychiatry
Earlier, Relmada Therapeutics Announced Publication Of Results From The Phase 3 Reliance I Study of REL-1017 In The Journal Of Clinical Psychiatry
Relmada Therapeutics, Inc. (NASDAQ:RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced the publication of REL-1017 clinical data from the Reliance I Study in the peer-reviewed journal, The Journal of Clinical Psychiatry. The article is titled, "Efficacy and Safety of Esmethadone (REL-1017) in Patients with Major Depressive Disorder and Inadequate Response to Standard Antidepressants: A Phase 3 Randomized Controlled Trial", and is available online at Link To Title.
Relmada Therapeutics, Inc.（納斯達克:RLMD）是一家專注於治療中樞神經系統疾病的晚期生物技術公司，今天宣佈在同行評議的期刊《臨床精神病學雜誌》中發佈了來自Reliance I研究的REL-1017臨床數據。該文章的題目是“Efficacy and Safety of Esmethadone（REL-1017）in Patients with Major Depressive Disorder and Inadequate Response to Standard Antidepressants: A Phase 3 Randomized Controlled Trial”，在線可鏈接至標題。
譯文內容由第三人軟體翻譯。